Immunai CTO and Co-Founder Luis Voloch on Using Deep Learning to Develop New Drugs - Ep. 176 - podcast episode cover

Immunai CTO and Co-Founder Luis Voloch on Using Deep Learning to Develop New Drugs - Ep. 176

Jul 31, 202228 min
--:--
--:--
Listen in podcast apps:

Episode description

What if we could map our immune system to create drugs that can help our bodies win the fight against cancer and other diseases? That’s the big idea behind immunotherapy. The problem: the immune system is incredibly complex. Enter Immunai, a biotechnology company that’s using AI technology to map the human immune system and speed the development of new immunotherapies against cancer and autoimmune diseases. On this episode of NVIDIA’s AI Podcast, host Noah Kravitz spoke with Luis Voloch, CTO and Co-Founder of Immunai, about tackling the challenges of the immune system with a machine learning and data science mindset.
Immunai CTO and Co-Founder Luis Voloch on Using Deep Learning to Develop New Drugs - Ep. 176 | NVIDIA AI Podcast - Listen or read transcript on Metacast